A Phase 2 interventional study of UBT251 and Placebo in Overweight and Obesity, sponsored by Novo Nordisk A/S. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 49th largest by planned enrollment of the 166 interventional ones that give a count, is one of 47 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 8 of the 65 other live ones, and was the 163rd registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
207 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 14 · Phase 3 62 · Phase 4 4
First in 2007; this study’s year is marked. 47 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 333 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 138 across the 166 interventional studies, 1,260 across the 41 observational. Of the 138 that completed or were terminated, 39 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
26 of the studies in Obesity by Novo Nordisk A/S that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
Add all 26 to your calendar (.ics) → With an account.
Among the 207 studies in Obesity by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's planned enrollment of 333 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Part C: Japanese, Chinese or non-Asian participants (all self-reported):
Age at the time of signing the :
at screening (overweight and obesity should be due to excess adipose tissue, as judged by the investigator):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive multiple dose levels subcutaneously.
Drug: UBT251
Participants will receive placebo matched to UBT251 subcutaneously.
Drug: Placebo
Participants will be randomized to receive multiple dose levels subcutaneously.
Drug: UBT251
Participants will be randomized to receive multiple dose levels subcutaneously.
Drug: UBT251
Participants will be randomized to receive multiple dose levels subcutaneously.
Drug: UBT251
Participants will be randomized to receive 2 dose levels subcutaneously.
Drug: UBT251
Participants will be randomized to receive a single dose level subcutaneously.
Drug: UBT251
Participants will receive placebo matching one of the UBT251 arms subcutaneously.
Drug: Placebo
Participants will be randomized to receive dose level 1 subcutaneously.
Drug: UBT251
Participants will be randomized to receive dose level 2 subcutaneously.
Drug: UBT251
Participants will be randomized to receive dose level 3 subcutaneously.
Drug: UBT251
UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.
Placebo matched to UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.
Part A - Number of treatment emergent adverse events (TEAEs)
Measured as Number of events.
Time frame: From baseline (week 0) to end of study (week 33)
Part B - Relative change in body weight
Measured as percentage of body weight.
Time frame: From baseline (week 0) to end of treatment (week 28)
Part C- AUC; the area under the UBT251 plasma concentration time curve
Measured as hour\*nanomoles per liter (h\*nmol/L)
Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 43)
Part A - Relative change in body weight
Measured as percentage of body weight.
Time frame: From baseline (week 0) to end of treatment (week 28)
Part A - Change in body weight
Measured as kilogram (kg).
Time frame: From baseline (week 0) to end of treatment (week 28)
Part A - AUC; the area under the UBT251 plasma concentration-time curve
Measured as h\*nmol/L
Time frame: From pre-dose on day 1 to end of study (week 33)
Part A - Cmax; the maximum plasma concentration of UBT251
Measured as nanomole per liter (nmol/L)
Time frame: From pre-dose on day 1 to end of study (week 33)
Part B - Change in body weight
Measured as kg.
Time frame: From baseline (week 0) to end of treatment (week 28)
Part B - Change in waist circumference
Measured as centimetre (cm).
Time frame: From baseline (week 0) to end of treatment (week 28)
Part B - Number of TEAEs
Measured as number of events
Time frame: From baseline (week 0) to end of study (week 33)
Part C - Cmax; the maximum plasma concentration of UBT251
Measured as nmol/L
Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 43)
Part C - Number of treatment-emergent adverse events (TEAEs)
Measured as number of events.
Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 43)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 11 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: UBT251